Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder
NCT00353379Phase 4Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Sep 1995
- Primary completion
- May 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizotypal personality disorder (STPD) comparing Guanfacine with Placebo (2 arms). Primary endpoint: Performance on tests of sustained attention, episodic memory, and working memory at 6 weeks. Started Sep 1995; status: terminated.
02
Drugs
guanfacine
03
Conditions
schizotypal personality disorder (STPD)
Beyond the preview
Go deeper on NCT00353379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00353379.